Details
Stereochemistry | RACEMIC |
Molecular Formula | C24H19ClN4O4 |
Molecular Weight | 462.885 |
Optical Activity | ( + / - ) |
Defined Stereocenters | 0 / 1 |
E/Z Centers | 0 |
Charge | 0 |
SHOW SMILES / InChI
SMILES
COC(=O)NC1=NC2=CC(=CC=C2N1)C3(O)N(C(=O)C4=C3C=CC=C4)C5=C(C)C=CC(Cl)=C5
InChI
InChIKey=MMNNTJYFHUDSKL-UHFFFAOYSA-N
InChI=1S/C24H19ClN4O4/c1-13-7-9-15(25)12-20(13)29-21(30)16-5-3-4-6-17(16)24(29,32)14-8-10-18-19(11-14)27-22(26-18)28-23(31)33-2/h3-12,32H,1-2H3,(H2,26,27,28,31)
Molecular Formula | C24H19ClN4O4 |
Molecular Weight | 462.885 |
Charge | 0 |
Count |
|
Stereochemistry | RACEMIC |
Additional Stereochemistry | No |
Defined Stereocenters | 0 / 1 |
E/Z Centers | 0 |
Optical Activity | ( + / - ) |
BMS-908662 (previously known as XL281) is a small molecule Raf kinase inhibitor that lies immediately downstream of RAS and are key components of the RAS/RAF/MEK/ERK kinase-signaling pathway. Bristol-Myers Squibb has received an exclusive worldwide license to develop and commercialize antineoplastic agent XL281. BMS-908662 participated in phase I development for the treatment of patients with melanoma and in combination with cetuximab for patients with colorectal cancer. However, further, development has been discontinued.
Approval Year
PubMed
Title | Date | PubMed |
---|---|---|
Paradoxical activation of T cells via augmented ERK signaling mediated by a RAF inhibitor. | 2014 Jan |
|
Phase I study of XL281 (BMS-908662), a potent oral RAF kinase inhibitor, in patients with advanced solid tumors. | 2015 Apr |
|
Clinico-morphological features of BRAF inhibition-induced proliferative skin lesions in cancer patients. | 2015 Jan 1 |
Patents
Sample Use Guides
In Vivo Use Guide
Sources: https://clinicaltrials.gov/ct2/show/NCT01086267
Capsules, Oral, escalating doses starting at 25 mg, every 12 hours (Q 12 h), Continuously
Route of Administration:
Oral
Substance Class |
Chemical
Created
by
admin
on
Edited
Fri Dec 15 16:04:32 GMT 2023
by
admin
on
Fri Dec 15 16:04:32 GMT 2023
|
Record UNII |
DW2NWI3TFN
|
Record Status |
Validated (UNII)
|
Record Version |
|
-
Download
Name | Type | Language | ||
---|---|---|---|---|
|
Common Name | English | ||
|
Common Name | English | ||
|
Systematic Name | English | ||
|
Common Name | English | ||
|
Systematic Name | English | ||
|
Systematic Name | English | ||
|
Common Name | English | ||
|
Common Name | English |
Code System | Code | Type | Description | ||
---|---|---|---|---|---|
|
100000174997
Created by
admin on Fri Dec 15 16:04:32 GMT 2023 , Edited by admin on Fri Dec 15 16:04:32 GMT 2023
|
PRIMARY | |||
|
DW2NWI3TFN
Created by
admin on Fri Dec 15 16:04:32 GMT 2023 , Edited by admin on Fri Dec 15 16:04:32 GMT 2023
|
PRIMARY | |||
|
DB12854
Created by
admin on Fri Dec 15 16:04:32 GMT 2023 , Edited by admin on Fri Dec 15 16:04:32 GMT 2023
|
PRIMARY | |||
|
870603-16-0
Created by
admin on Fri Dec 15 16:04:32 GMT 2023 , Edited by admin on Fri Dec 15 16:04:32 GMT 2023
|
PRIMARY | |||
|
CHEMBL3545027
Created by
admin on Fri Dec 15 16:04:32 GMT 2023 , Edited by admin on Fri Dec 15 16:04:32 GMT 2023
|
PRIMARY | |||
|
56931136
Created by
admin on Fri Dec 15 16:04:32 GMT 2023 , Edited by admin on Fri Dec 15 16:04:32 GMT 2023
|
PRIMARY |
Related Record | Type | Details | ||
---|---|---|---|---|
|
TARGET -> INHIBITOR |
Related Record | Type | Details | ||
---|---|---|---|---|
|
ACTIVE MOIETY |